|Mr. David A. Ricks||Chairman, CEO & Pres||4.4M||N/A||1968|
|Mr. Joshua L. Smiley||Sr. VP & CFO||2.13M||N/A||1970|
|Dr. Daniel M. Skovronsky||Sr. VP, Chief Scientific Officer & Pres of Lilly Research Labs||2.14M||N/A||1975|
|Mr. Jacob S. Van Naarden||Chief Operating Officer of Loxo Oncology||N/A||N/A||1985|
|Mr. Donald A. Zakrowski||Chief Accounting Officer & VP of Fin.||N/A||N/A||N/A|
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It offers endocrinology products for diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and paediatric growth conditions. The company also provides neuroscience products for treating depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; migraine and episodic cluster headache; attention-deficit hyperactivity disorder; and schizophrenia. In addition, it offers immunology products for the treatment of rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis; oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and products to treat erectile dysfunction and benign prostatic hyperplasia. Eli Lilly and Company primarily has collaborations with Incyte Corporation; Pfizer Inc.; Dicerna Pharmaceuticals, Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; and Avidity Biosciences, Inc., as well as AbCellera Biologics Inc. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Eli Lilly and Company’s ISS Governance QualityScore as of December 3, 2019 is 9. The pillar scores are Audit: 1; Board: 10; Shareholder Rights: 9; Compensation: 2.